Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.38 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.35 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.35 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.35 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22716997 | 0.86 | PDE3B (0.39) | NR4A2DHODHPDE3BPDE3ACYP46A1 | |
| SCHEMBL29454537 | 0.86 | PDE3B (0.39) | NR4A2DHODHPDE3BPDE3ACYP46A1 | |
| SCHEMBL22717203 | 0.83 | CYP46A1 (0.44) | NR4A2DHODHPDE3BPDE3ACYP46A1 | |
| SCHEMBL22724703 | 0.76 | DHODH (0.40) | NR4A2DHODHPDE3BPDE3AEGLN1 | |
| SCHEMBL25281510 | 0.75 | CNR1 (0.43) | NR4A2DHODHPDE3BPDE3ACYP46A1 | |
| SCHEMBL25478034 | 0.75 | AAK1 (0.42) | — | |
| SCHEMBL22866621 | 0.73 | CYP46A1 (0.40) | NR4A2DHODHPDE3BPDE3ACYP46A1 | |
| SCHEMBL23703636 | 0.72 | KDM4E (0.42) | — | |
| SCHEMBL30111861 | 0.72 | KDM4E (0.42) | — | |
| SCHEMBL29261587 | 0.71 | POLQ (0.52) | CYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226298-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2022-07-21 | — | — | US | disclosed |
| EP-3976576-A1 | GPR40 AGONISTS | Kallyope, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020242943-A1 | GPR40 AGONISTS | KALLYOPE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020242943-A1 | GPR40 AGONISTS | KALLYOPE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226298-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | NR4A2 166/4885DHODH 3019/4885PDE3B 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.